Company intelligence / Profile preview

Araclon Biotech

Zaragoza, Zaragoza, Spainaraclon.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Araclon Biotech has completed recruitment for Phase II clinical trials of its Alzheimer's vaccine ABvac40, with positive data from the first part of the trial showing potential to slow disease progression. The vaccine induces a strong immune response characterized by increased anti-Aβ40 titers while Aβ40 levels rise in plasma. The company has also obtained CE mark for its early-stage Alzheimer's disease diagnostic tests.[8][10]

Therapeutic areas: Neurology
Modalities: Vaccines (active immunotherapy)diagnostic tests
Industry: Biotech

Drug pipeline

2 assets

ABvac40

1 more asset in the full pipeline.

Request access →

Partnerships

Grifols

Beyond the preview

Go deeper on Araclon Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Araclon Biotech.

Explore the full profile